🎉 M&A multiples are live!
Check it out!

Shanghai Hile Bio-Tech Valuation Multiples

Discover revenue and EBITDA valuation multiples for Shanghai Hile Bio-Tech and similar public comparables like AstraZeneca India, GSK India, and Prescient Therapeutics.

Shanghai Hile Bio-Tech Overview

About Shanghai Hile Bio-Tech

Shanghai Hile Bio-Technology Co Ltd is a veterinary biological product manufacturer integrating research and development, production, sales, and service. The company has over 40 categories of poultry, livestock, and pets. The company provides services for the prevention of livestock diseases, improving the health of livestock and poultry, and improving the production efficiency of farmers, and is able to provide comprehensive solutions and an authoritative veterinary expert service system.


Founded

1981

HQ

China
Employees

n/a

Website

hile-bio.com

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

$679M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Shanghai Hile Bio-Tech Financials

Shanghai Hile Bio-Tech has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Shanghai Hile Bio-Tech achieved revenue of $33.2M and an EBITDA of $13.9M.

Shanghai Hile Bio-Tech expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Shanghai Hile Bio-Tech valuation multiples based on analyst estimates

Shanghai Hile Bio-Tech P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $33.2M n/a XXX XXX XXX
Gross Profit $26.7M $24.4M XXX XXX XXX
Gross Margin 80% NaN% XXX XXX XXX
EBITDA $13.9M n/a XXX XXX XXX
EBITDA Margin 42% NaN% XXX XXX XXX
Net Profit $7.4M $16.8M XXX XXX XXX
Net Margin 22% NaN% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Shanghai Hile Bio-Tech Stock Performance

As of April 15, 2025, Shanghai Hile Bio-Tech's stock price is CNY 8 (or $1).

Shanghai Hile Bio-Tech has current market cap of CNY 5.1B (or $701M), and EV of CNY 4.9B (or $679M).

See Shanghai Hile Bio-Tech trading valuation data

Shanghai Hile Bio-Tech Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$679M $701M XXX XXX XXX XXX n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Shanghai Hile Bio-Tech Valuation Multiples

As of April 15, 2025, Shanghai Hile Bio-Tech has market cap of $701M and EV of $679M.

Shanghai Hile Bio-Tech's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Shanghai Hile Bio-Tech's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Shanghai Hile Bio-Tech and 10K+ public comps

Shanghai Hile Bio-Tech Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $679M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA n/a XXX XXX XXX
P/E n/a XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF n/a XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Shanghai Hile Bio-Tech Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Shanghai Hile Bio-Tech Valuation Multiples

Shanghai Hile Bio-Tech's NTM/LTM revenue growth is n/a

Shanghai Hile Bio-Tech's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.

Over next 12 months, Shanghai Hile Bio-Tech's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Shanghai Hile Bio-Tech's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Shanghai Hile Bio-Tech and other 10K+ public comps

Shanghai Hile Bio-Tech Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth n/a XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee n/a XXX XXX XXX XXX
S&M Expenses to Revenue 13% XXX XXX XXX XXX
G&A Expenses to Revenue 15% XXX XXX XXX XXX
R&D Expenses to Revenue 10% XXX XXX XXX XXX
Opex to Revenue 49% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Shanghai Hile Bio-Tech Public Comps

See public comps and valuation multiples for Vaccines & Immunotherapies comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
CSL XXX XXX XXX XXX XXX XXX
Imugene XXX XXX XXX XXX XXX XXX
Prescient Therapeutics XXX XXX XXX XXX XXX XXX
GSK India XXX XXX XXX XXX XXX XXX
AstraZeneca India XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Shanghai Hile Bio-Tech M&A and Investment Activity

Shanghai Hile Bio-Tech acquired  XXX companies to date.

Last acquisition by Shanghai Hile Bio-Tech was  XXXXXXXX, XXXXX XXXXX XXXXXX . Shanghai Hile Bio-Tech acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Shanghai Hile Bio-Tech

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Shanghai Hile Bio-Tech

When was Shanghai Hile Bio-Tech founded? Shanghai Hile Bio-Tech was founded in 1981.
Where is Shanghai Hile Bio-Tech headquartered? Shanghai Hile Bio-Tech is headquartered in China.
Is Shanghai Hile Bio-Tech publicy listed? Yes, Shanghai Hile Bio-Tech is a public company listed on SHG.
What is the stock symbol of Shanghai Hile Bio-Tech? Shanghai Hile Bio-Tech trades under 603718 ticker.
When did Shanghai Hile Bio-Tech go public? Shanghai Hile Bio-Tech went public in 2015.
Who are competitors of Shanghai Hile Bio-Tech? Similar companies to Shanghai Hile Bio-Tech include e.g. CSL, Imugene, Prescient Therapeutics, GSK India.
What is the current market cap of Shanghai Hile Bio-Tech? Shanghai Hile Bio-Tech's current market cap is $701M
Is Shanghai Hile Bio-Tech profitable? Yes, Shanghai Hile Bio-Tech is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.